Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Robert M. Knabb
Observed names:
R Knabb,
R M Knabb,
R. M. KNABB,
R. M. Knabb,
R.M Knabb,
R.M. KNABB,
R.M. Knabb,
Robert Knabb,
Robert M Knabb
show all 9
Institution:
Bristol-Myers Squibb (United States)
Observed institutions:
DuPont (United States),
Henry Ford Health,
Washington University in St. Louis,
University of Michigan,
Bristol-Myers Squibb (United States),
Michigan Medicine,
University of Virginia,
Temple University
show all 8
OpenAlex ID:
A5084860922
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
2011
·
Samuel Z. Goldhaber
, Alain Leizorovicz
, et al.
·
New England Journal of Medicine
·
548
PDF
Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa
2007
·
Donald J. P. Pinto
, Michael J. Orwat
, et al.
·
Journal of Medicinal Chemistry
·
413
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies
2008
·
P.C. WONG
, E.J. CRAIN
, et al.
·
Journal of Thrombosis and Haemostasis
·
301
The selective inhibition of thrombin by peptides of boroarginine.
1990
·
C Kettner
, L Mersinger
, et al.
·
Journal of Biological Chemistry
·
255
Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor
2004
·
Mimi L. Quan
, Patrick Y. S. Lam
, et al.
·
Journal of Medicinal Chemistry
·
192
Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa
2001
·
Donald J. P. Pinto
, Michael J. Orwat
, et al.
·
Journal of Medicinal Chemistry
·
174
Factor Xa Inhibitors: Next-Generation Antithrombotic Agents
2010
·
Donald J. P. Pinto
, Joanne M. Smallheer
, et al.
·
Journal of Medicinal Chemistry
·
138
Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator.
1985
·
K A Fox
, A K Robison
, et al.
·
Circulation
·
111
PDF
Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans
2009
·
Donglu Zhang
, Kan He
, et al.
·
Drug Metabolism and Disposition
·
107
Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
1994
·
S A Mousa
, J M Bozarth
, et al.
·
Circulation
·
101
PDF
Structure-Based Design of Novel Guanidine/Benzamidine Mimics: Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants
2003
·
Patrick Y. S. Lam
, Charles G. Clark
, et al.
·
Journal of Medicinal Chemistry
·
99
Blood Flow Regulation by Adenosine in Heart, Brain, and Skeletal Muscle
1983
·
Robert M. Berne
, H. Richard Winn
, et al.
·
Springer eBooks
·
96
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
2011
·
Kan He
, Joseph M. Luettgen
, et al.
·
European Journal of Drug Metabolism and Pharmacokinetics
·
94
Effects of dipyridamole on myocardial adenosine and active hyperemia
1984
·
R. M. Knabb
, J. M. Gidday
, et al.
·
American Journal of Physiology-Heart and Circulatory Physiology
·
87
Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 1
1999
·
Mimi L. Quan
, Ann Y. Liauw
, et al.
·
Journal of Medicinal Chemistry
·
82
Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 2
1999
·
Mimi L. Quan
, Christopher D. Ellis
, et al.
·
Journal of Medicinal Chemistry
·
77
Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2‘-(aminosulfonyl)[1,1‘-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor
2003
·
James R. Pruitt
, Donald J. P. Pinto
, et al.
·
Journal of Medicinal Chemistry
·
76
In Vivo Characterization of a New Synthetic Thrombin Inhibitor
1992
·
Robert M Knabb
, Charles A Kettner
, et al.
·
Thrombosis and Haemostasis
·
74
Nonpeptide Factor Xa Inhibitors: I. Studies with SF303 and SK549, a New Class of Potent Antithrombotics
2000
·
Pancras C. Wong
, Mimi L. Quan
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
73
Isoxazolines and isoxazoles as factor Xa inhibitors
2000
·
James R Pruitt
, Donald J Pinto
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
68
Consistent parallel relationships among myocardial oxygen consumption, coronary blood flow, and pericardial infusate adenosine concentration with various interventions and beta-blockade in the dog.
1983
·
R M Knabb
, S W Ely
, et al.
·
Circulation Research
·
68
PDF
Enhancement of salvage of reperfused ischemic myocardium by diltiazem
1986
·
Robert M. Knabb
, Thomas L. Rosamond
, et al.
·
Journal of the American College of Cardiology
·
66
PDF
1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
2006
·
Donald J.P. Pinto
, Michael J. Orwat
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
65
Production and Purification of Recombinant Hirudin Expressed in the Methylotrophic YeastPichia pastoris
1996
·
Stuart A. Rosenfeld
, Daniel Nadeau
, et al.
·
Protein Expression and Purification
·
63
Sulfation of O-Demethyl Apixaban: Enzyme Identification and Species Comparison
2009
·
Lifei Wang
, Nirmala Raghavan
, et al.
·
Drug Metabolism and Disposition
·
61
Show more works
View as search
Works count:
124
Citation count:
5,637
H-index:
41
I10-index:
94
Year
Topic
Type
